General Motors Co. (NYSE: GM) on Monday posted total June U.S. sales of 243,155 vehicles, a decrease of 4.7% compared with June 2016. Retail deliveries fell 3.1 points in the month to 202,908 million units, and fleet deliveries dipped 1.1 percentage points for the calendar year to account for 19.9% of total monthly sales.
GM��s new vehicle sales for May were forecast at 252,000 by analysts at Kelley Blue Book (KBB). The analysts also estimated an average transaction price of $38,507, down 0.1% month over month but up 0.2% year over year. KBB does not include applied consumer incentives to its calculation.
The company said June’s average transaction price was $35,657, up nearly $400 per vehicle compared to May’s average. The company also said that June incentive spending as reported by J.D. Power averaged 12% of the company’s average transaction price for the month.
June sales of the company’s top-selling Silverado pickup rose by 1.7% year over year to 50,515 units, while GMC Sierra sales tumbled 8.3% to 15,743 units.
Hot High Tech Stocks To Buy For 2019: Northern Oil and Gas, Inc.(NOG)
Advisors' Opinion:- [By Matthew DiLallo]
Shares of Northern Oil & Gas, Inc. (NYSEMKT:NOG) are flying high, up 12% as of 10:30 a.m. EDT, after the company reported better-than-expected first-quarter results.
- [By Ethan Ryder]
Northern Oil and Gas Inc. (NYSEAMERICAN:NOG) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $2.20.
Hot High Tech Stocks To Buy For 2019: Apricus Biosciences, Inc(APRI)
Advisors' Opinion:- [By Chris Lange]
Apricus Biosciences Inc. (NASDAQ: APRI) has a PDUFA goal date for completion of the FDA��s review of the Vitaros NDA set on February 17. Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the U.S. ED treatment market. So far Vitaros has been approved in Canada, Mexico and certain countries in Europe, Latin America and the Middle East. Shares of Apricus were last seen at $2.22, with a 52-week range of $0.86 to $3.49 and a consensus price target of $3.50.
- [By Paul Ausick]
Apricus Biosciences Inc. (NASDAQ: APRI) also dropped about 38% Monday to post a new 52-week low of $0.26. Shares closed at $0.42 on Friday and the stock’s 52-week high is $3.34. Volume was more than three times the daily average of around 1.4 million shares. The company is considering its options after the U.S. FDA directed the firm to develop a new formulation for its erectile dysfunction drug, Vitaros.
- [By William Romov]
California-based Apricus Biosciences Inc. (Nasdaq: APRI) develops treatments in the areas of urology and rheumatology. Its lead product, Vitaros, is a topically applied cream for the treatment of erectile dysfunction (ED).
Hot High Tech Stocks To Buy For 2019: Controladora Vuela Compania de Aviacion, S.A.B. de C.V.(VLRS)
Advisors' Opinion:- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers Prothena Corporation plc (NASDAQ: PRTA) shares dipped 69 percent to $11.48 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Gridsum Holding Inc. (NASDAQ: GSUM) fell 44.3 percent to $4.06. Gridsum reported suspension of audit report on financial statements. Flotek Industries, Inc. (NYSE: FTK) shares declined 34.1 percent to $4.16 as the company issued weak revenue forecast for the first quarter. Akorn, Inc. (NASDAQ: AKRX) dropped 32.3 percent to $13.35 after Fresenius terminated its merger deal with Akorn. Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 31.2 percent to $13.44. Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron. Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) dropped 18 percent to $5.76. Controladora Vuela recently reported first-quarter results that showed a loss for the quarter. Imperial Capital downgraded Controladora Vuela Compania de Aviacion from Outperform to In-Line. Atossa Genetics Inc. (NASDAQ: ATOS) fell 18.2 percent to $2.8797 after declining 19.35 percent on Friday. Alcoa Corporation (NYSE: AA) fell 12.3 percent to $52.63. Luby's, Inc. (NYSE: LUB) shares declined 10.3 percent to $2.448 following Q2 results. Aceto Corporation (NASDAQ: ACET) shares tumbled 10 percent to $2.26. Pier 1 Imports, Inc. (NYSE: PIR) dipped 9.7 percent - [By Adam Levine-Weinberg]
In late 2016 and early 2017, profitability deteriorated rapidly at Mexican budget airline Volaris (NYSE:VLRS)�due to market disruptions caused by the U.S. presidential election. Fears about a crackdown on trade or immigration under President Trump led to a sharp drop in the Mexican peso and a downturn in travel demand. However, Volaris seemed to be on the mend by this time last year, and its stock price rebounded to more than $15 last July.
- [By Travis Hoium]
Shares of Mexican airline Controladora Vuela Co Avcn SA CV (NYSE:VLRS) plunged as much as 20.3% in trading Monday after announcing earnings that led to fears of growing competition. At 12:25 p.m. EDT shares were still down 16.6% on the day.�
Hot High Tech Stocks To Buy For 2019: MKS Instruments, Inc.(MKSI)
Advisors' Opinion:- [By Logan Wallace]
MKS Instruments, Inc. (NASDAQ:MKSI) Director Peter Hanley sold 250 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $113.70, for a total transaction of $28,425.00. Following the completion of the transaction, the director now owns 3,241 shares in the company, valued at $368,501.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
- [By Stephan Byrd]
MKS Instruments, Inc. (NASDAQ:MKSI) Director Richard S. Chute sold 1,988 shares of the firm’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $110.75, for a total value of $220,171.00. Following the completion of the sale, the director now directly owns 10,103 shares of the company’s stock, valued at $1,118,907.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Hot High Tech Stocks To Buy For 2019: Opko Health Inc(OPK)
Advisors' Opinion:- [By Keith Speights]
ARMO BioSciences (NASDAQ:ARMO), Opko Health (NASDAQ:OPK), and Arrowhead Pharmaceuticals (NASDAQ:ARWR) chalked up huge gains over the last five days. What sent these biotech stocks into orbit? And are they still smart picks for investors? Here's what you need to know about the fantastic week for ARMO, Opko, and Arrowhead along with what could be next for each stock.
- [By ]
In the Lightning Round, Cramer was bullish on Opko Health (OPK) , Zendesk (ZEN) , ServiceNow (NOW) , Box (BOX) and Constellation Brands (STZ) .
Cramer was bearish on Thor Industries (THO) and Hain Celestial Group (HAIN) .
- [By ]
Opko Health (OPK) : "The stock has been slow, and I think that's a mistake."
Thor Industries (THO) : "They had expenses and inventory go up and it's been hurt by both. Those are negatives."
- [By Maxx Chatsko]
Shares of OPKO Health (NASDAQ:OPK)�suffered a free fall today, losing as much as 23%. The drop occurred after the company announced that a crucial Medicare Administrative Contractor issued a draft local coverage determination (LCD) for the highly anticipated 4Kscore diagnostic test. That's a mouthful, but the implications are simple.
- [By Lisa Levin] Gainers Amedica Corporation (NASDAQ: AMDA) rose 31.3 percent to $4.11 in pre-market trading after climbing 181.98 percent on Tuesday. ZAGG Inc (NASDAQ: ZAGG) rose 18.7 percent to $13.65 in pre-market trading after the company posted better-than-expected Q1 earnings. TripAdvisor, Inc. (NASDAQ: TRIP) rose 18.6 percent to $46.00 in pre-market trading after the company reported stronger-than-expected results for its first quarter on Tuesday. TransEnterix, Inc. (NYSE: TRXC) shares rose 15 percent to $2.08 in pre-market trading after reporting Q4 results. Axon Enterprise, Inc. (NASDAQ: AAXN) rose 9.8 percent to $49.00 in pre-market trading following a big Q1 beat. The company raised its fiscal 2018 sales growth guidance from 16-18 percent to 18-20 percent. Centennial Resource Development, Inc. (NASDAQ: CDEV) shares rose 8.1 percent to $21.06 in pre-market trading following Q1 results. OPKO Health, Inc. (NASDAQ: OPK) shares rose 6.8 percent to $3.44 in pre-market trading following Q1 beat. Tel-Instrument Electronics Corp. (NYSE: TIK) rose 6.7 percent to $3.20 in pre-market trading after surging 25.37 percent on Tuesday. KBS Fashion Group Limited (NASDAQ: KBSF) rose 6.4 percent to $5.84 in pre-market trading after jumping 9.36 percent on Tuesday. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) rose 6.6 percent to $8.26 in pre-market trading after reporting Q2 earnings. New Relic, Inc. (NYSE: NEWR) rose 6.3 percent to $82.00 in pre-market trading following Q4 results. Match Group, Inc. (NASDAQ: MTCH) rose 5.8 percent to $38.43 in pre-market trading after reporting upbeat Q1 earnings. Prestige Brands Holdings, Inc. (NYSE: PBH) rose 5.2 percent to $30.62 in pre-market trading.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Paul Ausick]
Opko Health Inc. (NASDAQ: OPK) dropped nearly 7% Wednesday to post a new 52-week low of $4.28 after closing at $4.60 on Tuesday. The stock’s 52-week high is $9.01. Volume was around 7.7 million, nearly double the daily average of around 4.3 million. The company had no specific news.
Hot High Tech Stocks To Buy For 2019: ESSA Pharma Inc.(EPIX)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin]
Losers Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering. InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday. Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81. Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections. Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results. LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss. Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit. Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings. Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss. Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight. Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings. The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results. Arcadia Biosciences, Inc. (N
No comments:
Post a Comment